A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Authors: Hortobagyi, G.N. ^{1, ∗}, Lacko, A. ², Sohn, J. ³, Cruz, F. ⁴, Ruiz Borrego, M. ⁵, Manikhas, A. ⁶, Hee Park, Y. ⁷, Stroyakovskiy, D. ⁸, Yardley, D.A. ⁹, Huang, C.-S. ¹⁰, Fasching, P.A. ¹¹, Crown, J. ¹², Bardia, A. ¹³, Chia, S. ¹⁴, Im, S.-A. ¹⁵, Martin, M. ¹⁶, Loi, S. ¹⁷, Xu, B. ¹⁸, Hurvitz, S. ¹⁹, Barrios, C. ²⁰, Untch, M. ²¹, Moroose, R. ²², Visco, F. ²³, Parnizari, F. ²⁴, Zarate, J.P. ²⁵, Li, Z. ²⁵, Waters, S. ²⁶, Chakravartty, A. ²⁵, Slamon, D. ¹³

Source: In Annals of Oncology February 2025 36(2):149-157

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Authors: Agostinetto, E. ^{1, ∗, †}, Pfeiler, G. ^{2, †}, Hlauschek, D. ³, Mayer, E.L. ⁴, Lambertini, M. ^{5, 6}, de Azambuja, E. ¹, Bellet-Ezquerra, M. ⁷, Meisel, J.L. ⁸, Rubovszky, G. ⁹, Zdenkowski, N. ¹⁰, Novik, Y. ¹¹, Ruiz-Borrego, M. ^{12, 13}, Gelmon, K.A. ¹⁴, Mamounas, E.P. ¹⁵, Iwata, H. ¹⁶, Lu, D.R. ¹⁷, Soelkner, L. ³, Fesl, C. ³, Gnant, M. ^{3, 18, †}, DeMichele, A. ^{19, †}

Source: In ESMO Open January 2025 10(1)

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Authors: Guerrero-Zotano, Á., Pérez-García, J.M., Ruiz-Borrego, M., Bermejo, B., Gil-Gil, M., de la Haba, J., Alba Conejo, E., Quiroga, V., Carañana, V., Urruticoechea, A., Morales, S., Bellet, M., Antón, A., Fernández-Abad, M., Sánchez-Rovira, P., Calabuig, L., Pérez-Escuredo, J., Sampayo-Cordero, M., Cortés, J., Llombart-Cussac, A.

Source: In ESMO Open October 2024 9(10)

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Authors: Vaz Batista, M., Pérez-García, J.M., Cortez, P., Garrigós, L., Fernández-Abad, M., Gion, M., Martínez-Bueno, A., Saavedra, C., Teruel, I., Fernandez-Ortega, A., Servitja, S., Ruiz-Borrego, M., de la Haba-Rodríguez, J., Martrat, G., Pérez-Escuredo, J., Alcalá-López, D., Sampayo-Cordero, M., Braga, S., Cortés, J., Llombart-Cussac, A.

Source: In ESMO Open September 2024 9(9)

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Authors: Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E.M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M.R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J.P.O., Morrow, C.J., Sykes, A., Baird, R.D.

Source: In Annals of Oncology August 2024 35(8):707-717

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Authors: Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., O’Shaughnessy, J.

Source: In Annals of Oncology August 2021 32(8):994-1004

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Authors: Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., Gil-Gil, M.

Source: In Annals of Oncology April 2021 32(4):488-499

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Authors: Carcas, L., Castrellon, A., Chan, D., Cheong, K., Choi, B., Coleman, M., Conlin, A., Dichmann, R., Ellison, D., Erickson, N., Gore, I., Hansen, V., Huang, D., Hufnagel, D., Kass, F., Kendall, S.D., Kozloff, M., Lawler, W., Nahum, K.D., Pistilli, B., Reyes, E., Seeger, J., Somer, R., Chiu, E. Tan, Thomas, G., Tkaczuk, K., Vaziri, I., Wade, J., Wilkinson, M., Barcenas, C.H., Hurvitz, S.A., Di Palma, J.A., Bose, R., Chien, A.J., Iannotti, N., Marx, G., Brufsky, A., Litvak, A., Ibrahim, E., Alvarez, R.H., Ruiz-Borrego, M., Chan, N., Manalo, Y., Kellum, A., Trudeau, M., Thirlwell, M., Garcia Saenz, J., Hunt, D., Bryce, R., McCulloch, L., Rugo, H.S., Tripathy, D., Chan, A.

Source: In Annals of Oncology September 2020 31(9):1223-1230

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

Authors: Ethier, J.L., Ocaña, A., Rodríguez Lescure, A., Ruíz, A., Alba, E., Calvo, L., Ruíz-Borrego, M., Santaballa, A., Rodríguez, C.A., Crespo, C., Ramos, M., Gracia Marco, J., Lluch, A., Álvarez, I., Casas, M., Sánchez-Aragó, M., Carrasco, E., Caballero, R., Amir, E., Martin, M.

Source: In European Journal of Cancer May 2018 94:199-205

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Authors: Martín, M. ^*, Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., Ruiz Borrego, M., Khan, Q.J., Beck, J.T., Ramos Vázquez, M., Urban, P., Goteti, S., Di Tomaso, E., Massacesi, C., Delaloge, S.

Source: In Annals of Oncology February 2017 28(2):313-320

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Authors: Slamon, D.¹, Lipatov, O.², Nowecki, Z.³, McAndrew, N.¹, Kukielka-Budny, B.⁴, Stroyakovskiy, D.⁵, Yardley, D. A.⁶, Huang, C.-S.⁷, Fasching, P. A.⁸, Crown, J.⁹, Bardia, A.¹⁰, Chia, S.¹¹, Im, S.-A.¹², Ruiz-Borrego, M.^13,14, Loi, S.¹⁵, Xu, B.¹⁶, Hurvitz, S.¹⁷, Barrios, C.¹⁸, Untch, M.¹⁹, Moroose, R.²⁰

Source: New England Journal of Medicine; 3/21/2024, Vol. 390 Issue 12, p1080-1091, 12p

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Authors: Albanell, J. ^*, González, A., Ruiz-Borrego, M., Alba, E., García-Saenz, J.A., Corominas, J.M., Burgues, O., Furio, V., Rojo, A., Palacios, J., Bermejo, B., Martínez-García, M., Limon, M.L., Muñoz, A.S., Martín, M., Tusquets, I., Rojo, F., Colomer, R., Faull, I., Lluch, A.

Source: In Annals of Oncology March 2012 23(3):625-631

150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial

Authors: Llombart Cussac, A., Pérez-García, J.M., Pare Brunet, L., Villacampa Javierre, G., Brasó-Maristany, F., Gion Cortes, M., Schmid, P., Colleoni, M.A., Ruiz Borrego, M., Galván, P., Parker, J., Perou, C.M., Villagrasa Gonzalez, P., Guerrero, J.A., Sampayo-Cordero, M., Mancino, M., Prat, A., Cortés, J.

Source: In Annals of Oncology October 2023 34 Supplement 2:S240-S241

251P Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients

Authors: García-Sáenz, J.A., Spera, G., Pollán, M.A., Bermejo, B., Ruiz Borrego, M., Chan, A., Martin Jimenez, M., Guerrero Zotano, A.L., Calvo-Martinez, L., Rodríguez-Lescure, A., Arcusa Lanza, A., Chap, L.I., Crown, J.P., Bee-Munteanu, V., Casas, M., Polonio, O., Slamon, D.

Source: In Annals of Oncology October 2023 34 Supplement 2:S283-S284

Age–period–cohort analysis of breast cancer mortality rates in Andalucia (Spain)

Authors: Cayuela, A. ^*, Rodríguez-Domínguez, S., Ruiz-Borrego, M., Gili, M.

Source: In Annals of Oncology April 2004 15(4):686-688

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

Authors: Kalinsky, K., kevin.michael.kalinsky@emory.edu, Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., Dhesy-Thind, S., Rastogi, P., Alba, E., Delaloge, S., Martin, M., Kelly, C. M., Ruiz-Borrego, M., Gil-Gil, M., Arce-Salinas, C. H., Brain, E. G. C.

Source: New England Journal of Medicine; 12/16/2021, Vol. 385 Issue 25, p2336-2347, 12p

205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Authors: Cortés Salgado, A., Perez Garcia, J.M., Cortez Castedo, S.P., Gion Cortes, M., Morales Murillo, S., Blancas López-Barajas, I., Blanch, S., Calvo Plaza, I., Diaz Fernandez, N., Marmé, F., Martinez Bueno, A., Taberner Bonastre, M.T., De Laurentiis, M., Ruiz Borrego, M., Schmid, P., Guarneri, V., Gligorov, J., Sampayo-Cordero, M., Llombart Cussac, A., Cortés, J.

Source: In Annals of Oncology May 2022 33 Supplement 3:S221-S221

175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Authors: Cardoso, F., Juric, D., Lerebours, F., Krop, I., Ruiz Borrego, M., Neven, P., Park, Y.H., Yardley, D., Jhaveri, K., Arce, C., Gu, E., Akdere, M., Rugo, H.S.

Source: In Annals of Oncology May 2022 33 Supplement 3:S206-S207

93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Authors: Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz Borrego, M., Stradella, A., Bermejo De Las Heras, B., Escriva de Romani, S., Calvo-Martinez, L., Ribelles Entrena, N., Martinez, N., Albacar Miro, C.R., Colleoni, M.A., Atienza de Frutos, M., Sampayo-Cordero, M., Cortés, J., Perez Garcia, J.M., Llombart Cussac, A.

Source: In Annals of Oncology May 2022 33 Supplement 3:S166-S166

92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8

Authors: Jerusalem, G., Prat, A., Salgado, R.F., Reinisch, M., Saura, C., Ruiz Borrego, M., Nikolinakos, P., Filian, J., Ades, F., Huang, N., Mazzei-Abba, A., Tolaney, S.M.

Source: In Annals of Oncology May 2022 33 Supplement 3:S165-S166